Dr. Kari L. Ring, MD
Gynecologic Oncology (Gynecologic Oncology Physician)
- Medicare participating
At a glance
- Medical school
- University of Virginia School of Medicine (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 198
Licensed in Texas since 2014, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Medical school: University of Virginia School of Medicine
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gynecologic Oncology Physician primary
VA license 0101260252 -
Obstetrics & Gynecology Physician
TX license P8987 (first issued 2014; canc non-renewal)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Virginia Medical Center Charlottesville, VA
- Centra Health - Lynchburg Gen Hospital Lynchburg, VA
- Sentara Rmh Medical Center Harrisonburg, VA
- Augusta Health Fishersville, VA
- Uva Health Prince William Medical Center Manassas, VA
Medical groups
- University of Virginia Physicians Group (1,717 clinicians)
- Centra Medical Group LLC (724 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 198
- Services billed
- 423
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 20-29 minutes | 162 | 120 |
| Established patient office or other outpatient visit, 30-39 minutes | 142 | 57 |
| New patient office or other outpatient visit, 45-59 minutes | 26 | 26 |
| New patient office or other outpatient visit, 60-74 minutes | 22 | 22 |
| Removal of uterus, tubes, and/or ovaries through abdomen using an endoscope, 250.0 g or less | 12 | 12 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Letrozole Other prescribers in Charlottesville, VA | 24 |
| Eliquis (apixaban) Other prescribers in Charlottesville, VA | 22 |
| Ondansetron Hcl Other prescribers in Charlottesville, VA | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 2 companies reported 2 payments worth $1,115 in total to this clinician.
| Medical Device Business Services, Inc. | $1,010 |
|---|---|
| Ethicon US, LLC | $105 |
| Consulting Fee | $1,010 |
|---|---|
| Food and Beverage | $105 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Medical Device Business Services, Inc. Sep 23, 2025 | Consulting Fee Enseal; Harmonic; STRATAFIX · Energy | $1,010 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $13,144 in research payments for these studies, mostly to the institutions running them.
- A phase 3, randomized, double-blind, multicenter study of dostarlimab
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.